---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-019257"
form_type: "8-K"
ticker: "MLAB"
cik: "0000724004"
company_name: "MESA LABORATORIES INC /CO/"
filed_at: "2024-06-05T23:59:59+00:00"
generated_at: "2026-06-01T06:23:24.192325+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Mesa Labs Q4 net loss of $254.6M on $274.5M impairment; core organic revenues down 3.5%

## Summary
- Q4 revenue $58.9M (+6% YoY); core organic revenue declined 3.5% due to headwinds in Clinical Genomics and Biopharma.
- Full-year operating loss of $272.1M includes $274.5M non-cash impairment of goodwill and long-lived assets.
- Non-GAAP AOI excluding unusual items rose 26.3% in Q4 to $14.9M; full-year AOI +0.7% to $50.5M.
- Clinical Genomics division restructured with 17 position eliminations, expects ~$3M annual savings.
- SDC division grew 37.3% (including GKE China acquisition); BPD and CG declined organically.

## SEC filing metadata
- accession: 0001437749-24-019257
- form_type: 8-K
- ticker: MLAB
- cik: 0000724004
- company_name: MESA LABORATORIES INC /CO/
- filed_at: 2024-06-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/724004/000143774924019257/0001437749-24-019257-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/724004/000143774924019257/mlab20240531_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-019257
- JSON: https://secwatch.observer/filing/0001437749-24-019257.json
- Plain text: https://secwatch.observer/filing/0001437749-24-019257.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.